Lataa...
Drug Delivery to Melanoma Brain Metastases: Can Current Challenges Lead to New Opportunities?
Melanoma has a high propensity to metastasize to the brain, and patients with melanoma brain metastases (MBM) have an extremely poor prognosis. The recent approval of several molecularly-targeted agents (e.g., BRAF, MEK inhibitors) and biologics (anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies) has...
Tallennettuna:
| Julkaisussa: | Pharmacol Res |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5565722/ https://ncbi.nlm.nih.gov/pubmed/28634084 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.phrs.2017.06.008 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|